Skip to main content

Biocryst Pharmaceuticals Inc

BCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0000882796

No open-market purchases or sales by Biocryst Pharmaceuticals Inc insiders were filed in the last 90 days; 319 institutions reported holding it in 13F filings for Q2 2026, worth $2.64B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Biocryst Pharmaceuticals Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Biocryst Pharmaceuticals Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Biocryst Pharmaceuticals Inc
NameTitleLast reported holdingLast filingFilings, past year
Stonehouse Jon PDirector1,340,419Sep 2, 20267
Milne Jill C.Director33,226Sep 2, 20265
Milano VincentDirector109,642Sep 2, 20265
McKee Amy EDirector47,821Sep 2, 20266
Frank StevenDirector36,747Sep 2, 20265
Levin Alan GDirector79,565Jun 15, 20261
Galson Steven KDirector27,794Jun 15, 20261
Sanders MachelleDirector45,936Jun 15, 20262
Heggie TheresaDirector80,646Jun 15, 20262
Barnes Alane PChief Legal Officer400,703May 15, 20266
Menon SandeepChief R&D Officer205,150Apr 7, 20261
Gayer Charles KPresident and CCO952,583Dec 23, 20253
Ghias BabarChief Financial Officer268,700Dec 19, 20251
Hutson Nancy JDirector99,138Jun 16, 20250
Thackray Helen M.Chief R&D Officer377,318Apr 2, 20250
Doyle AnthonyChief Financial Officer377,867Dec 23, 20240
Aselage SteveDirector70,159Jun 14, 20240
Abercrombie George BDirector36,431Jun 14, 20240
Lee Kenneth B JrDirector68,863Jun 15, 20230
Ingram Robert AlexanderDirector100,198Mar 2, 20230
Jones Michael LExec. Director, Finance - PAO16,653Dec 21, 20220
Babu Yarlagadda SChief Discovery Officer298,541Nov 16, 20220
Sheridan William PChief Medical Officer37,954Mar 14, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 19, 2026 (view filing)May 181 dayMcKee Amy EDirectorSSale−11.2K$8.97−$100.3K−26.3%31.3K after
May 15, 2026 (view filing)May 132 daysBarnes Alane PChief Legal OfficerSSale−62.5K$9.54−$596.3K−13.5%400.7K after10b5-1
Mar 24, 2026 (view filing)Mar 204 daysHeggie TheresaDirectorSSale−49.9K$10.11−$504.8K−43.3%65.4K after
Mar 18, 2026 (view filing)Mar 162 daysBarnes Alane PChief Legal OfficerSSale−150.0K$9.15−$1.37M−27.2%400.7K after10b5-1
Dec 23, 2025 (view filing)Dec 221 dayBarnes Alane PChief Legal OfficerSSale−21.8K$7.65−$166.6K−5.2%398.8K after10b5-1
Dec 16, 2025 (view filing)Dec 151 dayBarnes Alane PChief Legal OfficerSSale−21.2K$7.65−$162.3K−6.3%315.7K after10b5-1
Dec 3, 2025 (view filing)Dec 1-32 daysBarnes Alane PChief Legal OfficerSSale−161.7K$7.20−$1.16M−31.9%345.5K after3 lots10b5-1
Nov 17, 2025 (view filing)Nov 134 daysSanders MachelleDirectorSSale−9.60K$7.14−$68.5K−23.9%30.6K after10b5-1
Aug 15, 2025 (view filing)Aug 132 daysHeggie TheresaDirectorSSale−70.0K$8.51−$595.7K−51.7%65.4K after
Dec 16, 2024 (view filing)Dec 133 daysHutson Nancy JDirectorSSale−7.00K$7.54−$52.8K−7.5%86.6K after10b5-1
Jun 25, 2024 (view filing)Jun 241 dayMcKee Amy EDirectorSSale−8.60K$6.32−$54.4K−23.6%27.8K after
Jun 17, 2024 (view filing)Jun 17Same daySanders MachelleDirectorSSale−4.69K$6.00−$28.1K−14.5%27.7K after
Jun 14, 2024 (view filing)Jun 14Same dayHeggie TheresaDirectorSSale−6.70K$6.11−$40.9K−11.2%52.9K after
May 31, 2024 (view filing)May 301 dayLevin Alan GDirectorPPurchase+7.86K$6.36+$50.0K+21.2%45.0K after
May 29, 2024 (view filing)May 245 daysAselage SteveDirectorPPurchase+2.50K$6.40+$16.0KNew position2.50K after
May 22, 2024 (view filing)May 202 daysHutson Nancy JDirectorPPurchase+5.00K$6.38+$31.9K+6.1%86.8K after
May 22, 2024 (view filing)May 202 daysMilano VincentDirectorPPurchase+15.0K$6.25+$93.8K+28.8%67.0K after
May 15, 2024 (view filing)May 141 dayDoyle AnthonyChief Financial OfficerPPurchase+36.3K$5.57+$202.2K+15.8%266.7K after
May 15, 2024 (view filing)May 141 dayThackray Helen M.Chief R&D OfficerPPurchase+30.0K$5.86+$175.8K+12.4%272.1K after
May 15, 2024 (view filing)May 132 daysGalson Steven KDirectorPPurchase+21.9K$5.49+$120.5K+74.1%51.6K after
May 15, 2024 (view filing)May 132 daysBarnes Alane PChief Legal OfficerPPurchase+5.00K$5.53+$27.6K+1.7%300.8K after
May 15, 2024 (view filing)May 132 daysStonehouse Jon PPresident & CEOPPurchase+30.0K$5.55+$166.5K+2.7%1.13M after
May 15, 2024 (view filing)May 132 daysGayer Charles KChief Commercial OfficerPPurchase+30.0K$5.47+$164.1K+10.8%307.5K after
Jun 15, 2023 (view filing)Jun 15Same daySanders MachelleDirectorSSale−4.00K$7.98−$31.9K−13.5%25.6K after
Jun 15, 2023 (view filing)Jun 141 dayHutson Nancy JDirectorSSale−12.9K$8.04−$103.4K−13.6%81.8K after
Apr 5, 2023 (view filing)Apr 32 daysThackray Helen M.Chief R&D OfficerSSale−7.00K$8.29−$58.0K−3.3%207.3K after10b5-1
Feb 2, 2023 (view filing)Feb 11 dayStonehouse Jon PPresident & CEOSSale−100.0K$10.38−$1.04M−9.0%1.01M after
Dec 19, 2022 (view filing)Dec 154 daysStonehouse Jon PPresident & CEOSSale−14.1K$10.90−$153.7K−1.6%887.7K after
Dec 19, 2022 (view filing)Dec 154 daysThackray Helen M.Chief R&D OfficerSSale−3.13K$10.89−$34.0K−2.3%133.3K after
Dec 19, 2022 (view filing)Dec 154 daysDoyle AnthonyChief Financial OfficerSSale−5.70K$10.90−$62.1K−3.4%164.0K after
Dec 19, 2022 (view filing)Dec 154 daysGayer Charles KChief Commercial OfficerSSale−6.10K$10.90−$66.5K−2.8%211.6K after
Dec 19, 2022 (view filing)Dec 154 daysJones Michael LExec. Director, Finance - PAOSSale−445$10.90−$4.85K−4.0%10.8K after
Dec 19, 2022 (view filing)Dec 154 daysBarnes Alane PChief Legal OfficerSSale−4.17K$10.88−$45.4K−2.1%198.8K after
Dec 2, 2022 (view filing)Dec 11 dayJones Michael LExec. Director, Finance - PAOSSale−8.60K$13.01−$111.9K−43.4%11.2K after
Dec 2, 2022 (view filing)Dec 1-21 dayStonehouse Jon PPresident & CEOSSale−297.6K$12.94−$3.85M−24.8%901.8K after2 lots
Nov 16, 2022 (view filing)Nov 142 daysBabu Yarlagadda SChief Discovery OfficerSSale−31.5K$13.88−$437.4K−9.5%298.5K after
Apr 20, 2022 (view filing)Apr 182 daysAbercrombie George BDirectorSSale−5.00K$11.04−$55.2K−100.0%0 after
Apr 4, 2022 (view filing)Apr 13 daysThackray Helen M.Chief R&D OfficerSSale−7.60K$16.20−$123.1K−5.3%136.4K after
Mar 14, 2022 (view filing)Mar 104 daysSheridan William PChief Medical OfficerSSale−161.1K$16.88−$2.72M−80.9%38.0K after2 lots
Mar 9, 2022 (view filing)Mar 72 daysBabu Yarlagadda SChief Discovery OfficerSSale−20.0K$17.16−$343.2K−8.0%230.1K after
Mar 3, 2022 (view filing)Mar 12 daysJones Michael LExec. Director, Finance - PAOSSale−2.30K$17.20−$39.6K−17.0%11.2K after
Feb 16, 2022 (view filing)Feb 151 dayAbercrombie George BDirectorSSale−5.00K$18.50−$92.5K−100.0%0 after
Jan 13, 2022 (view filing)Jan 112 daysStonehouse Jon PPresident & CEOSSale−184.0K$15.04−$2.77M−16.9%901.6K after
Dec 9, 2021 (view filing)Dec 72 daysBabu Yarlagadda SChief Discovery OfficerSSale−30.1K$12.20−$367.2K−12.3%215.1K after
Nov 24, 2021 (view filing)Nov 24Same dayMilano VincentDirectorPPurchase+7.50K$12.19+$91.4K+75.0%17.5K after
Nov 24, 2021 (view filing)Nov 231 dayDoyle AnthonyChief Financial OfficerPPurchase+35.3K$12.48+$440.0K+60.3%93.7K after
Nov 17, 2021 (view filing)Nov 152 daysAbercrombie George BDirectorSSale−5.00K$12.27−$61.4K−100.0%0 after
Oct 19, 2021 (view filing)Oct 154 daysHutson Nancy JDirectorSSale−105.0K$15.40−$1.62M−61.7%65.1K after
Sep 17, 2021 (view filing)Sep 152 daysAbercrombie George BDirectorSSale−5.00K$15.06−$75.3K−100.0%0 after
Sep 15, 2021 (view filing)Sep 132 daysLee Kenneth B JrDirectorSSale−6.00K$15.35−$92.1K−19.8%24.3K after